Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million ≈ $6.49 Million USD) by net assets (CN¥735.65 Million ≈ $107.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Hainan Huluwa Pharmaceutical Group Co Lt fund operations to measure how many days the company can operate on defensive assets alone.

Hainan Huluwa Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Fujian SBS Zipper Science Tech SHE:002098	0.056x
Mezzion Pharma Co.Ltd KQ:140410	-0.391x
DWS Municipal Income Trust NYSE:KTF	0.041x
Chalice Mining Ltd AU:CHN	-0.099x
GSR III Acquisition Corp. Ordinary Shares NASDAQ:GSRT	-0.002x
LH Shopping Centers Leasehold BK:LHSC	0.011x
Xinjiang Sayram Modern Agriculture Co Ltd SHG:600540	-1.899x
Hangzhou Coco Healthcare Products Co.Ltd. SHE:301009	-0.012x

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Hainan Huluwa Pharmaceutical Group Co Lt.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥458.02 Million ≈ $67.02 Million	CN¥136.85 Million ≈ $20.03 Million	0.299x	+248.94%
2024-12-31	CN¥743.28 Million ≈ $108.77 Million	CN¥-149.12 Million ≈ $-21.82 Million	-0.201x	-923.26%
2023-12-31	CN¥1.16 Billion ≈ $169.65 Million	CN¥28.25 Million ≈ $4.13 Million	0.024x	-89.64%
2022-12-31	CN¥1.02 Billion ≈ $148.57 Million	CN¥238.71 Million ≈ $34.93 Million	0.235x	+113.48%
2021-12-31	CN¥930.52 Million ≈ $136.16 Million	CN¥102.48 Million ≈ $15.00 Million	0.110x	+2958.79%
2020-12-31	CN¥916.48 Million ≈ $134.11 Million	CN¥3.30 Million ≈ $482.88K	0.004x	-98.40%
2019-12-31	CN¥643.94 Million ≈ $94.23 Million	CN¥144.51 Million ≈ $21.15 Million	0.224x	+326.73%
2018-12-31	CN¥604.61 Million ≈ $88.47 Million	CN¥31.80 Million ≈ $4.65 Million	0.053x	-79.46%
2017-12-31	CN¥351.38 Million ≈ $51.42 Million	CN¥89.96 Million ≈ $13.16 Million	0.256x	-49.28%
2016-12-31	CN¥128.69 Million ≈ $18.83 Million	CN¥64.96 Million ≈ $9.51 Million	0.505x	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$356.56 Million

CN¥2.44 Billion CNY

Market Cap Rank

#14087 Global

#4212 in China

Share Price

CN¥6.09

Change (1 day)

-0.65%

52-Week Range

CN¥6.09 - CN¥10.20

All Time High

CN¥48.21